Are biotechs underestimating regulatory groundwork
Bio matters
Related Posts
Lilly receives UK approval for pirtobrutinib in relapsed blood cancers
MHRA grants conditional authorisation for treatment targeting mantle cell lymphoma Eli Lilly and Company has received conditional marketing authorisation from the MHRA for pirtobrutinib (Jaypirca […]
NHS to ensure people eligible for very high-risk breast screening are referred
Secondary breast cancer is an important risk factor after receiving radiotherapy for Hodgkin lymphoma NHS England has responded to the recent ministerial statement by newly […]
Cognitive decline in early Alzheimer’s could stem from serotonin loss
MCI patients had 25% lower levels of serotonin compared to healthy patients Researchers from Johns Hopkins Medicine have suggested that serotonin loss […]